These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38315878)

  • 1. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
    Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; García-Sanz R; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyż J; Fernández De Larrea C; Belada D; Libby E; Matous J; Motta M; Siddiqi T; Tani M; Trněný M; Minnema MC; Buske C; Leblond V; Treon SP; Trotman J; Wu B; Yu Y; Shen Z; Chan WY; Schneider J; Allewelt H; Cohen A; Dimopoulos MA
    Blood Adv; 2024 Apr; 8(7):1639-1650. PubMed ID: 38315878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
    Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; Sanz RG; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyz J; Fernández de Larrea C; Belada D; Libby E; Matous JV; Motta M; Siddiqi T; Tani M; Trneny M; Minnema MC; Buske C; Leblond V; Trotman J; Chan WY; Schneider J; Ro S; Cohen A; Huang J; Dimopoulos M
    Blood; 2020 Oct; 136(18):2038-2050. PubMed ID: 32731259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial.
    Tedeschi A; Tam CS; Owen RG; Buske C; Leblond V; Dimopoulos M; Garcia-Sanz R; Castillo JJ; Trotman J; Treon SP; Yang K; Tang B; Allewelt H; Patel S; Chan WY; Cohen A; Chen S; Barnes G
    Future Oncol; 2024; 20(25):1789-1798. PubMed ID: 39072392
    [No Abstract]   [Full Text] [Related]  

  • 4. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.
    Dimopoulos M; Sanz RG; Lee HP; Trneny M; Varettoni M; Opat S; D'Sa S; Owen RG; Cull G; Mulligan S; Czyz J; Castillo JJ; Motta M; Siddiqi T; Gironella Mesa M; Granell Gorrochategui M; Talaulikar D; Zinzani PL; Askari E; Grosicki S; Oriol A; Rule S; Kloczko J; Tedeschi A; Buske C; Leblond V; Trotman J; Chan WY; Michel J; Schneider J; Tan Z; Cohen A; Huang J; Tam CS
    Blood Adv; 2020 Dec; 4(23):6009-6018. PubMed ID: 33284944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
    Lim KJC; Tam CS
    Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
    [No Abstract]   [Full Text] [Related]  

  • 6. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.
    Dimopoulos MA; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; Garcia-Sanz R; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyz J; Fernández de Larrea C; Belada D; Libby E; Matous J; Motta M; Siddiqi T; Tani M; Trněný M; Minnema MC; Buske C; Leblond V; Treon SP; Trotman J; Chan WY; Schneider J; Allewelt H; Patel S; Cohen A; Tam CS
    J Clin Oncol; 2023 Nov; 41(33):5099-5106. PubMed ID: 37478390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
    Tam CS; LeBlond V; Novotny W; Owen RG; Tedeschi A; Atwal S; Cohen A; Huang J; Buske C
    Future Oncol; 2018 Sep; 14(22):2229-2237. PubMed ID: 29869556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.
    Treon SP; Sarosiek S; Castillo JJ
    Blood; 2024 Apr; 143(17):1702-1712. PubMed ID: 38211337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
    Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP
    Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930
    [No Abstract]   [Full Text] [Related]  

  • 10. [The efficacy and safety of Bruton tyrosine kinase inhibitors as monotherapy in the treatment of newly diagnosed patients with Waldenström macroglobulinemia].
    Tao Y; Xu YL; Wang S; Wang L; Zhao WL
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):490-494. PubMed ID: 37550205
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
    Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
    Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.
    Treon SP; Gustine J; Meid K; Yang G; Xu L; Liu X; Demos M; Kofides A; Tsakmaklis N; Chen JG; Munshi M; Chan G; Dubeau T; Raje N; Yee A; O'Donnell E; Hunter ZR; Castillo JJ
    J Clin Oncol; 2018 Sep; 36(27):2755-2761. PubMed ID: 30044692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia.
    An G; Zhou D; Cheng S; Zhou K; Li J; Zhou J; Xie L; Jin J; Zhong L; Yan L; Guo H; Du C; Zhong J; Yu Y; Wu B; Qiu L
    Clin Cancer Res; 2021 Oct; 27(20):5492-5501. PubMed ID: 34253577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib.
    Moslehi JJ; Furman RR; Tam CS; Salem JE; Flowers CR; Cohen A; Zhang M; Zhang J; Chen L; Ma H; Brown JR
    Blood Adv; 2024 May; 8(10):2478-2490. PubMed ID: 38502198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia.
    Treon SP; Meid K; Gustine J; Yang G; Xu L; Liu X; Patterson CJ; Hunter ZR; Branagan AR; Laubach JP; Ghobrial IM; Palomba ML; Advani R; Castillo JJ
    J Clin Oncol; 2021 Feb; 39(6):565-575. PubMed ID: 32931398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia.
    Treon SP; Meid K; Hunter ZR; Flynn CA; Sarosiek SR; Leventoff CR; White TP; Cao Y; Roccaro AM; Sacco A; Demos MG; Guerrera ML; Kofides A; Liu X; Xu L; Patterson CJ; Munshi M; Tsakmaklis N; Yang G; Ghobrial IM; Branagan AR; Castillo JJ
    Blood; 2021 Oct; 138(17):1535-1539. PubMed ID: 34289017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
    Buske C; Tedeschi A; Trotman J; García-Sanz R; MacDonald D; Leblond V; Mahe B; Herbaux C; Matous JV; Tam CS; Heffner LT; Varettoni M; Palomba ML; Shustik C; Kastritis E; Treon SP; Ping J; Hauns B; Arango-Hisijara I; Dimopoulos MA
    J Clin Oncol; 2022 Jan; 40(1):52-62. PubMed ID: 34606378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibrutinib in previously treated Waldenström's macroglobulinemia.
    Treon SP; Tripsas CK; Meid K; Warren D; Varma G; Green R; Argyropoulos KV; Yang G; Cao Y; Xu L; Patterson CJ; Rodig S; Zehnder JL; Aster JC; Harris NL; Kanan S; Ghobrial I; Castillo JJ; Laubach JP; Hunter ZR; Salman Z; Li J; Cheng M; Clow F; Graef T; Palomba ML; Advani RH
    N Engl J Med; 2015 Apr; 372(15):1430-40. PubMed ID: 25853747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BTK Inhibitors in the Frontline Management of Waldenström Macroglobulinemia.
    Varettoni M; Matous JV
    Hematol Oncol Clin North Am; 2023 Aug; 37(4):707-717. PubMed ID: 37246088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy.
    Castillo JJ; Sarosiek SR; Gustine JN; Flynn CA; Leventoff CR; White TP; Meid K; Guerrera ML; Kofides A; Liu X; Munshi M; Tsakmaklis N; Hunter ZR; Patterson CJ; Branagan AR; Treon SP
    Blood Adv; 2022 Feb; 6(3):1015-1024. PubMed ID: 34965304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.